drugset / Trial / NCT01472510

Ranibizumab in Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy

NCT01472510

RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to confirm that the investigational drug Ranibizumab given by injection into the eye is safe and effective to use in people with diabetic macular edema (DME).

Timeline

Start
2011-12
Primary completion
2013-07
Completion
2014-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ranibizumab Monoclonal antibody 0.5 mg Intravitreal